Intertrust Expands ExpressPlay Platform to Provide Seamless DRM Interoperability, Conditional Access, Audience Analytics, and Targeted Advertising
Intertrust Technologies Corporation today announced a major expansion of Intertrust ExpressPlay™, its cloud platform that provides content distributors, network operators, and broadcasters with a single service that satisfies all their media monetization requirements in a highly cost-effective and efficient way. The platform is the first of its kind to combine content protection and management with audience understanding and targeted advertising to offer greater convenience, security, privacy and risk management in a single solution.
Traditionally, companies distributing Internet video procured these services from two or more vendors, creating risk, additional cost, and confusion. ExpressPlay provides convenience at a significantly lower price, and is built on years of R&D embodied in Intertrust’s seminal patent portfolio.
Intertrust expands its traditional ExpressPlay DRM platform, which to date is the only cloud-based platform that supports all major DRM formats. In a major leap forward in DRM systems, ExpressPlay introduces a new Universal DRM SDK that promises to end cross-device DRM format conflicts decisively. Service providers building applications with the ExpressPlay Universal SDK can use all major DRMs without custom integration for each one. The Universal DRM SDK also supports DASH CENC to native FairPlay, and offers the protected (DRM) DASH stack for iOS, which doesn’t exist natively. This means that service providers can reduce multiple asset formats, streamline their workflows and deliver premium content using the native DRM.
The new platform also uses the Intertrust Personagraph™ consumer data platform to provide server-side and client-side advertising, and audience understanding. A network operator or broadcaster can now use ExpressPlay to deploy and manage content in a common secure format, provide targeted ads using their own infrastructure and run analytics on their users’ data securely and privately without dependencies on competitors.
Intertrust ExpressPlay now includes,
- ExpressPlay Universal DRM™ (uDRM): Intertrust’s leading multi-DRM platform that supports Adobe Access, Apple FairPlay, Google Widevine, Marlin DRM, and Microsoft PlayReady. The new Universal DRM (uDRM) SDK helps reduce costs by eliminating the need to distribute multiple versions of protected assets. It overcomes the challenges of the diverse device landscape (flavors of Android, iOS, etc), and efficiently implements offline playback of content on mobile devices. uDRM minimizes the need for complex backend systems and professional services.
- ExpressPlay CA™: A new Marlin-based Conditional Access System (CAS) that allows broadcasters and network operators to deliver card-free, powerful CAS capabilities using the same Marlin DRM engine used for broadband DRM. One engine supports two security models and results in substantial savings over traditional limited CAS.
- ExpressPlay Audience™: An advanced customer data platform that leverages Intertrust’s multi-billion user Personagraph consumer data platform. Audience provides understanding, advanced analytics, device graphs, and retail and marketing technology functions in a private and secure manner.
- ExpressPlay Ads™: A custom white-label advertising platform that uses ExpressPlay Audience to insert personalized ads into protected content streams on mobile, TV, and web platforms. The platform supports both server-side and client-side ad insertion technology to reach a broad range of devices in a highly scalable and efficient manner.
This is the first platform of its kind that provides convenience, security, privacy, and risk management. The components can be used jointly as a complete system or separately.
Intertrust will showcase ExpressPlay and related partner demos at IBC 2017 at the RAI in Amsterdam in Hall 5, Booth 15 between September 15-19, 2017.
About Intertrust Technologies Corporation
Intertrust provides trusted computing products and services to leading global corporations – from mobile and CE manufacturers and service providers to enterprise software platform companies. These products include the world’s leading digital rights management, software tamper resistance and privacy-driven data platforms for digital advertising, marketing technologies, DNA analysis, and IoT.
Founded in 1990, Intertrust is based in Silicon Valley, with regional offices in London, Tokyo, Seoul and Beijing. The Company has a legacy of invention, and its fundamental contributions in the areas of computer security and digital trust are globally recognized. Intertrust holds hundreds of patents that are key to Internet security, trust, and privacy management components of operating systems, trusted mobile code and networked operating environments, web services, and cloud computing. Additional information is available at intertrust.com, or follow us on Twitter or LinkedIn.
Brian Regan (for Intertrust), 908-399-7161
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an